Loading
A phase 1/2 trial of Peluntamig, Carboplatin, Etoposide in small-cell lung cancer and prostate cancer, run by Phanes Therapeutics, now recruiting.
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) is a phase 1/2 interventional study registered as NCT05652686 by Phanes Therapeutics, with 203 participants planned, started 2023-09-05 and due to reach its primary completion in 2027-12. Interventions recorded: Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin. Conditions listed: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lurbinectedin, Etoposide, Atezolizumab, Carboplatin.
Shares Lurbinectedin, Etoposide, Atezolizumab, Carboplatin.
Shares Etoposide, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
Shares Extrapulmonary neuroendocrine carcinoma, Etoposide, Atezolizumab, Small-cell lung cancer.
Shares Phanes Therapeutics, Paclitaxel / nab-paclitaxel, Small-cell lung cancer.
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/